| CAS No.: | 518048-05-0 |
|---|---|
| Formula: | C20h21fn6o5 |
| EINECS: | 610-733-3 |
| Type: | Pharmaceutical Intermediates |
| Appearance: | White Powder |
| Quality: | Refined |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Factory Supply Raltegravir Powder Used in Anti-HIV CAS 518048-05-0 Raltegravir
| Product name | Anti-HIV Drugs Raltegravir cas 518048-05-0 Raltegravir Powder |
| Appearance | white Powder |
| Cas | 518048-05-0 |
| Assay | 99% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
|
Raltegravir, also known as MK-0518, is an antiretroviral drug used to treat HIV infection. Raltegravir is a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI) with HIV-1 antiviral activity. Raltegravir binds to and inhibits integrase, an HIV enzyme that inserts viral genetic material into the genetic material of the infected human cell. Inhibition of integrase prevents insertion of HIV DNA into the human DNA genome, thus blocking HIV replication. It received approval by the U.S. Food and Drug Administration (FDA) in October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. |
|
Function Raltegravir ,It can be combined with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) -1 infection. It slows down HIV-1 infection by inhibiting the HIV integrase required for viral replication. When Rett Kawet with other anti HIV drugs can reduce the number of HIV in blood, and the increase of CD4+T cells known as the number of white blood cells, contribute to the anti infection. Show with Lito Bernard Vee, efavirenz, tenofovir for Ranave, the interaction of the goods and drug resistance no cross resistance and has a synergistic effect with multiple drugs. Raltegravir (RAL), , used to treat HIV infection. In a study of the drug as part of combination therapy, raltegravir exhibited potent and durable antiretroviral activity similar to that of efavirenz at 24 and 48 weeks but achieved HIV-1 RNA levels below detection at a more rapid rate. After 24 and 48 weeks of treatment, raltegravir did not result in increased serum levels of total cholesterol, low-density lipoprotein cholesterol, or triglycerides Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN. |
|
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}